Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

6 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Evaluation of therapeutic targeting of CCR7 in acute graft-versus-host disease.
Cuesta-Mateos C, Portero-Sainz I, García-Peydró M, Alcain J, Fuentes P, Juárez-Sánchez R, Pérez-García Y, Mateu-Albero T, Díaz-Fernández P, Vega-Piris L, Sánchez-López BA, Marcos-Jiménez A, Cardeñoso L, Gómez-García de Soria V, Toribio ML, Muñoz-Calleja C. Cuesta-Mateos C, et al. Among authors: juarez sanchez r. Bone Marrow Transplant. 2020 Oct;55(10):1935-1945. doi: 10.1038/s41409-020-0830-8. Epub 2020 Feb 21. Bone Marrow Transplant. 2020. PMID: 32086495
Effect of ibrutinib on CCR7 expression and functionality in chronic lymphocytic leukemia and its implication for the activity of CAP-100, a novel therapeutic anti-CCR7 antibody.
Mateu-Albero T, Juárez-Sánchez R, Loscertales J, Mol W, Terrón F, Muñoz-Calleja C, Cuesta-Mateos C. Mateu-Albero T, et al. Among authors: juarez sanchez r. Cancer Immunol Immunother. 2022 Mar;71(3):627-636. doi: 10.1007/s00262-021-03014-2. Epub 2021 Jul 23. Cancer Immunol Immunother. 2022. PMID: 34297159 Free PMC article.
CCR7 as a novel therapeutic target in t-cell PROLYMPHOCYTIC leukemia.
Cuesta-Mateos C, Fuentes P, Schrader A, Juárez-Sánchez R, Loscertales J, Mateu-Albero T, Vega-Piris L, Espartero-Santos M, Marcos-Jimenez A, Sánchez-López BA, Pérez-García Y, Jungherz D, Oberbeck S, Wahnschaffe L, Kreutzman A, Andersson EI, Mustjoki S, Faber E, Urzainqui A, Fresno M, Stamatakis K, Alfranca A, Terrón F, Herling M, Toribio ML, Muñoz-Calleja C. Cuesta-Mateos C, et al. Among authors: juarez sanchez r. Biomark Res. 2020 Oct 24;8:54. doi: 10.1186/s40364-020-00234-z. eCollection 2020. Biomark Res. 2020. PMID: 33110606 Free PMC article.
Evaluation of Natalizumab Pharmacokinetics and Pharmacodynamics: Toward Individualized Doses.
Serra López-Matencio JM, Pérez García Y, Meca-Lallana V, Juárez-Sánchez R, Ursa A, Vega-Piris L, Pascual-Salcedo D, de Vries A, Rispens T, Muñoz-Calleja C. Serra López-Matencio JM, et al. Among authors: juarez sanchez r. Front Neurol. 2021 Oct 7;12:716548. doi: 10.3389/fneur.2021.716548. eCollection 2021. Front Neurol. 2021. PMID: 34690914 Free PMC article.